FDA clears Iridex illumination probe for use with glaucoma laser

Iridex (Mountain View, CA) has received FDA approval to commercialize its G-Probe Illuminate probe, which offers combined transillumination and laser fiber for targeted transscleral cyclophotocoagulation (CPC; an advanced glaucoma procedure). The probe, which is powered by the company's Cyclo G6 glaucoma laser system, delivers transillumination to optimize its placement and, in turn, improve therapeutic outcomes.

Related: Iridex ophthalmic laser system for glaucoma treatment receives CE Mark approval

Studies have shown the ciliary body, the target tissue for a CPC treatment, naturally varies in location between patients, and cases of abnormal ocular size, high myopia, and post-corneal transplants generate even more challenges. The probe allows physicians to locate the ciliary body and deliver the laser treatment in a more targeted manner.

The probe has utility in the operating room or as an outpatient, office-based procedure for treating glaucoma.

For more information, please visit www.iridex.com.